Evidence map›Paper›PMID 35717166›Full record

ArticleBMC cancer2022

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.

Lutz van Heek, Colin Stuka, Helen Kaul, Horst Müller, Jasmin Mettler, Felicitas Hitz, Christian Baues, Michael Fuchs, Peter Borchmann, Andreas Engert and 3 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00736320 (HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00736320 phase3unknown statusnot on this map

HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET

TypeinterventionalSponsorUniversity of CologneRan2009 to 2021Enrolled1,150ConditionsHodgkin LymphomaArmsABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine), 20 Gy IFRT (Involved Field Radiotherapy)
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Role ofTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Impact of pretreatment PET/MRI on radiooncologic target delineation in Hodgkin's lymphoma: a case series.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Baseline and earlyCancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Lutz van HeekDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany. lutz.van-heek@uk-koeln.de.
Colin StukaDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Helen KaulFirst Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Horst MüllerFirst Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Jasmin MettlerDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Felicitas HitzSwiss Group for Clinical Cancer Research, Bern, Switzerland.
Christian BauesDepartment of Radiation Oncology and Cyberknife Center, Faculty of Medicine and UniversityHospital Cologne, University of Cologne, Cologne, Germany.
Michael FuchsFirst Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Peter BorchmannFirst Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Andreas EngertFirst Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen - Bonn - Cologne - Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Markus DietleinDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Conrad-Amadeus VoltinDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Carsten KobeDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
University of Cologne · DEUniversity Hospital Cologne · DEDüsseldorf University Hospital · DEHeinrich Heine University Düsseldorf · DESwiss Group For Clinical Cancer Research · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methods

resultsAll three threshold methods analyzed for MTV and TLG calculation showed a positive correlation with the PET response after 2 cycles chemotherapy. The largest area under the curve (AUC) was observed using the fixed threshold of SUV

conclusionsMTV and TLG do have a predictive value after two cycles ABVD in early stage Hodgkin lymphoma, particularly when using the fixed threshold of SUV

trial registrationClinicalTrials.gov NCT00736320 .

Indexed as

Fluorodeoxyglucose F18Hodgkin DiseaseAntineoplastic Combined Chemotherapy ProtocolsBleomycinDacarbazineDoxorubicinGlycolysisHumansPositron Emission Tomography Computed TomographyPrognosisProspective StudiesRadiopharmaceuticalsRetrospective StudiesTumor BurdenVinblastineBleomycinDacarbazineDoxorubicinFluorodeoxyglucose F18RadiopharmaceuticalsVinblastineFDG PETHodgkin lymphomaMetabolic tumor volumeResponse prediction

Identifiers

PMID35717166
PMCPMC9206242
OpenAlexW4283072465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.